NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
NeuroOne Medical Technologies (NASDAQ: NMTC) has appointed Dr. Parag G. Patil as Chief Medical Advisor (CMA), upgrading his role from the company's Scientific Advisory Board where he has served since 2018. Dr. Patil, a neurosurgeon-engineer with 20 years of experience, is currently an Associate Professor at the University of Michigan in multiple departments and serves as Associate Chair for Clinical and Translational Research.
Dr. Patil's expertise spans electrophysiology, imaging, and mathematical modeling, with a focus on developing improved therapies for paralysis, pain, and movement disorders using neural-interface devices. In his new role, he will assist with NeuroOne's clinical strategy, product development, physician education, and professional society partnerships while maintaining his faculty position.
NeuroOne Medical Technologies (NASDAQ: NMTC) ha nominato Dr. Parag G. Patil come Chief Medical Advisor (CMA), elevando il suo ruolo rispetto alla posizione nel Scientific Advisory Board dell'azienda, in cui ha operato dal 2018. Il Dr. Patil, neurochirurgo e ingegnere con 20 anni di esperienza, è attualmente Professore Associato presso l'Università del Michigan in diversi dipartimenti e ricopre il ruolo di Associate Chair per la Ricerca Clinica e Traslazionale.
La competenza del Dr. Patil abbraccia l'elettrofisiologia, l'imaging e la modellazione matematica, con un focus sullo sviluppo di terapie migliorate per paralisi, dolore e disturbi del movimento tramite dispositivi di interfaccia neurale. Nel suo nuovo incarico, supporterà NeuroOne nella strategia clinica, nello sviluppo dei prodotti, nella formazione dei medici e nelle collaborazioni con società professionali, mantenendo al contempo la sua posizione accademica.
NeuroOne Medical Technologies (NASDAQ: NMTC) ha designado a Dr. Parag G. Patil como Asesor Médico Principal (CMA), promoviendo su rol desde la Junta Asesora Científica de la compañía, donde ha servido desde 2018. El Dr. Patil, neurocirujano e ingeniero con 20 años de experiencia, es actualmente Profesor Asociado en la Universidad de Michigan en varios departamentos y funge como Subdirector para Investigación Clínica y Traslacional.
La experiencia del Dr. Patil abarca electrofisiología, imagenología y modelado matemático, con un enfoque en el desarrollo de terapias mejoradas para parálisis, dolor y trastornos del movimiento mediante dispositivos de interfaz neural. En su nuevo cargo, apoyará la estrategia clínica de NeuroOne, el desarrollo de productos, la educación médica y las asociaciones con sociedades profesionales, manteniendo su puesto académico.
NeuroOne Medical Technologies (NASDAQ: NMTC)는 Parag G. Patil 박사를 최고 의학 고문(CMA)으로 임명하며, 2018년부터 회사의 과학 자문 위원회에서 활동해온 그의 역할을 승격시켰습니다. Patil 박사는 20년 경력의 신경외과 의사이자 엔지니어로, 현재 미시간 대학교에서 여러 학과의 부교수이자 임상 및 전임상 연구 부의장을 맡고 있습니다.
Patil 박사의 전문 분야는 전기생리학, 영상학, 수학적 모델링을 포함하며, 신경 인터페이스 장치를 활용해 마비, 통증 및 운동 장애에 대한 개선된 치료법 개발에 집중하고 있습니다. 새 역할에서 그는 NeuroOne의 임상 전략, 제품 개발, 의사 교육 및 전문 학회와의 협력에 기여하면서 교수직도 유지할 예정입니다.
NeuroOne Medical Technologies (NASDAQ : NMTC) a nommé Dr Parag G. Patil au poste de Chief Medical Advisor (CMA), faisant évoluer son rôle depuis le conseil consultatif scientifique de l'entreprise où il siège depuis 2018. Le Dr Patil, neurochirurgien-ingénieur avec 20 ans d'expérience, est actuellement professeur associé à l'Université du Michigan dans plusieurs départements et occupe le poste de vice-président pour la recherche clinique et translationnelle.
L'expertise du Dr Patil couvre l'électrophysiologie, l'imagerie et la modélisation mathématique, avec un accent sur le développement de thérapies améliorées pour la paralysie, la douleur et les troubles du mouvement utilisant des dispositifs d'interface neuronale. Dans son nouveau rôle, il assistera NeuroOne dans la stratégie clinique, le développement de produits, la formation des médecins et les partenariats avec les sociétés professionnelles tout en conservant son poste universitaire.
NeuroOne Medical Technologies (NASDAQ: NMTC) hat Dr. Parag G. Patil zum Chief Medical Advisor (CMA) ernannt und damit seine Rolle von der wissenschaftlichen Beraterkommission des Unternehmens, der er seit 2018 angehört, aufgewertet. Dr. Patil, ein Neurochirurg und Ingenieur mit 20 Jahren Erfahrung, ist derzeit außerordentlicher Professor an der University of Michigan in mehreren Fachbereichen und fungiert als stellvertretender Vorsitzender für klinische und translationale Forschung.
Dr. Patils Fachgebiete umfassen Elektrophysiologie, Bildgebung und mathematische Modellierung mit Schwerpunkt auf der Entwicklung verbesserter Therapien für Lähmungen, Schmerzen und Bewegungsstörungen unter Verwendung von neuronalen Schnittstellen. In seiner neuen Funktion wird er NeuroOne bei der klinischen Strategie, Produktentwicklung, Ärztefortbildung und Partnerschaften mit Fachgesellschaften unterstützen und gleichzeitig seine akademische Position beibehalten.
- Appointment of highly qualified medical advisor with 20 years of experience in neurosurgery and engineering
- Dr. Patil's expertise aligns with company's focus on neural-interface devices and electrode technology
- Existing familiarity with company through Scientific Advisory Board membership since 2018
- None.
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies
EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company’s Scientific Advisory Board since 2018.
Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years’ experience serving patients and advancing innovative therapies to alleviate neurological disorders. After joining the faculty at the University of Michigan in 2005, he has served as an Associate Professor of Neurosurgery, Neurology, Anesthesiology, and Biomedical Engineering. He additionally serves as Associate Chair for Clinical and Translational Research and in leadership roles in diverse multi-disciplinary, multi-investigator research efforts and national societies. His academic goal is to utilize engineering and mathematical techniques, along with interdisciplinary collaboration, to improve neuroprosthetics and perform translational neuroscience research. His NIH and NSF-funded research focuses on electrophysiology, imaging, mathematical modeling, and the development of improved therapies for the treatment of paralysis, pain, and movement disorders using neural-interface devices.
Dr. Patil received a B.S. in electrical engineering from the Massachusetts Institute of Technology. After graduation, he was awarded a Marshall Scholarship to study Philosophy and Economics at Magdalen College, Oxford University in the UK. On returning to the U.S., Dr. Patil pursued combined medical and doctoral studies in biomedical engineering at Johns Hopkins University, followed by a neurosurgery residency at Duke University and a fellowship at the University of Toronto.
“We are privileged to welcome Dr. Patil, leveraging his over two decades of experience in clinical care and medical innovation in this new role,” said Dave Rosa, President and CEO of NeuroOne. “As we continue to develop our diagnostic and therapeutic platforms based on our unique thin film electrode technology, his vast experience and understanding of our technology makes him a perfect fit for the role. As CMA he will assist with NeuroOne’s clinical strategy, product development, physician education and partnerships with professional societies. He will leverage his experience with NeuroOne while maintaining his faculty position, providing valuable insights to help advance the commercialization of our next-generation electrode platform.”
Dr. Patil added, “NeuroOne is transforming the diagnosis and treatment of neurological disorders with its patented and disruptive technology platforms, and I am excited to take on this new role to further advance its use to reduce the number of surgeries and hospitalizations, while potentially improving efficacy. I look forward to working closer with the team at NeuroOne to drive the clinical development and implementation of this unique technology.”
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the development and clinical translation of the Company’s therapies to improve outcomes for patients and the physicians who care for them, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us
FAQ
Who is Dr. Parag Patil and what is his new role at NeuroOne (NMTC)?
What experience does Dr. Patil bring to NeuroOne (NMTC)?
What will be Dr. Patil's responsibilities as Chief Medical Advisor at NeuroOne (NMTC)?
What is NeuroOne's (NMTC) main business focus?
